A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Dabrafenib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Biomarker; Therapeutic Use
- 19 Dec 2017 Status changed from completed to discontinued.
- 28 Oct 2016 Status changed from active, no longer recruiting to completed.
- 18 Feb 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.